HTGM · Htg Molecular Diagnostics, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $6.37M | $8.91M | $8.55M | $19.20M | $14.76M | $14.76M |
| Cost of Revenue | $4.57M | $4.09M | $3.99M | $8.91M | $4.97M | $4.97M |
| Gross Profit | $1.79M | $4.81M | $4.56M | $10.29M | $9.79M | $9.79M |
| R&D | $6.78M | $6.09M | $6.08M | $10.57M | $12.60M | $10.00M |
| SG&A | $15.84M | $16.55M | $18.06M | $18.68M | $19.97M | $17.51M |
| Total Operating Expenses | $27.20M | $26.73M | $28.13M | $38.16M | $32.48M | $27.51M |
| D&A | $587.1K | $721.2K | $1.35M | $1.26M | $1.47M | $1.24M |
| Operating Income | ($20.83M) | ($17.82M) | ($19.59M) | ($18.96M) | ($16.16M) | ($17.72M) |
| Interest Expense | $856.7K | $1.06M | $1.02M | $957.5K | $901.8K | $1.31M |
| Income Tax | $10.8K | $22.5K | $14.4K | $3.4K | $3.5K | $2.9K |
| Net Income | ($21.59M) | ($17.15M) | ($20.87M) | ($19.30M) | ($16.45M) | ($18.96M) |
| EPS - Basic | ($29.66) | - | - | - | - | - |
| EPS - Diluted | ($29.66) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.21M | $9.60M | $22.40M | $7.62M | $8.43M | $9.97M |
| Accounts Receivable | $1.42M | $2.09M | $1.59M | $3.16M | $5.01M | $6.36M |
| Inventory | $909.3K | $1.99M | $1.49M | $1.27M | $1.31M | $1.18M |
| Accounts Payable | $1.16M | $1.65M | $1.35M | $1.66M | $1.85M | $2.44M |
| Current Assets | $15.65M | $27.19M | $32.87M | $41.37M | $38.00M | $17.95M |
| Total Assets | $17.78M | $30.46M | $35.20M | $45.12M | $43.77M | $21.26M |
| Current Liabilities | $8.27M | $9.94M | $7.24M | $8.90M | $7.02M | $13.34M |
| Long-term Debt | - | $5.18M | $8.57M | - | - | - |
| Total Liabilities | $12.39M | $20.06M | $20.71M | $21.15M | $22.68M | $24.32M |
| Stockholders' Equity | $5.39M | $10.40M | $14.48M | $23.97M | $21.09M | ($3.06M) |
| Retained Earnings | ($229.93M) | ($208.33M) | ($191.19M) | ($170.32M) | ($151.02M) | ($134.57M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($18.41M) | ($16.51M) | ($16.29M) | ($16.70M) | ($16.57M) | ($16.57M) |
| Investing Cash Flow | $12.42M | ($6.66M) | $18.73M | ($3.50M) | $3.28M | $3.28M |
| Financing Cash Flow | $8.60M | $10.39M | $9.05M | $19.39M | $15.75M | $15.75M |
| CapEx | $23.0K | $644.4K | $453.6K | $1.10M | $949.5K | $1.02M |
| Free Cash Flow | ($18.43M) | ($17.15M) | ($16.75M) | ($17.80M) | ($17.52M) | ($17.59M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 28.2% | 54.0% | 53.3% | 53.6% | 66.3% | 66.3% |
| Operating margin | -327.2% | -200.1% | -229.1% | -98.7% | -109.5% | -120.1% |
| EBITDA margin | -318.0% | -192.0% | -213.4% | -92.2% | -99.5% | -111.7% |
| Net margin | -339.2% | -192.5% | -244.1% | -100.5% | -111.5% | -128.5% |
| Free cash flow margin | -289.5% | -192.6% | -195.9% | -92.7% | -118.7% | -119.2% |
| FCF / Net income | 0.85 | 1.00 | 0.80 | 0.92 | 1.06 | 0.93 |
| R&D / Revenue | 106.5% | 68.4% | 71.1% | 55.0% | 85.4% | 67.7% |
| SG&A / Revenue | 248.8% | 185.8% | 211.3% | 97.3% | 135.3% | 118.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -121.5% | -56.3% | -59.3% | -42.8% | -37.6% | -89.2% |
| Return on equity | -400.5% | -164.9% | -144.1% | -80.5% | -78.0% | 619.7% |
| Return on invested capital | - | -90.4% | -67.1% | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.89 | 2.73 | 4.54 | 4.65 | 5.42 | 1.35 |
| Quick ratio | 1.78 | 2.53 | 4.34 | 4.51 | 5.23 | 1.26 |
| Cash ratio | 1.48 | 0.97 | 3.10 | 0.86 | 1.20 | 0.75 |
| Leverage | ||||||
| Debt / Equity | - | 0.50 | 0.59 | - | - | - |
| Debt / Assets | - | 0.17 | 0.24 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -24.3x | -16.7x | -19.1x | -19.8x | -17.9x | -13.6x |
| Equity multiplier | 3.30 | 2.93 | 2.43 | 1.88 | 2.08 | -6.95 |
| Liabilities / Assets | 0.70 | 0.66 | 0.59 | 0.47 | 0.52 | 1.14 |
| Efficiency | ||||||
| Asset turnover | 0.36 | 0.29 | 0.24 | 0.43 | 0.34 | 0.69 |
| Inventory turnover | 5.03 | 2.06 | 2.68 | 7.02 | 3.81 | 4.21 |
| Days sales outstanding | 82d | 86d | 68d | 60d | 124d | 157d |
| Days inventory outstanding | 73d | 177d | 136d | 52d | 96d | 87d |
| Days payable outstanding | 92d | 147d | 123d | 68d | 136d | 179d |
| Cash conversion cycle | 62d | 116d | 81d | 44d | 84d | 65d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -28.5% | 4.2% | -55.5% | 30.1% | 0.0% | 187.6% |
| Revenue CAGR (3y) | -30.8% | -15.5% | -16.6% | 55.2% | 64.3% | - |
| Revenue CAGR (5y) | -15.5% | 11.7% | 20.8% | - | - | - |
| Gross profit growth (YoY) | -62.7% | 5.6% | -55.7% | 5.2% | 0.0% | 881.9% |
| Operating income growth (YoY) | -16.9% | 9.0% | -3.3% | -17.3% | 8.8% | 27.2% |
| Net income growth (YoY) | -26.0% | 17.8% | -8.1% | -17.3% | 13.2% | 27.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -7.5% | -2.4% | 5.9% | -1.6% | 0.4% | 27.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -48.2% | -28.2% | -39.6% | 13.6% | - | 45.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$26.72M totalProduct And Product Related Services$8.91M · 33.3%
Product$5.17M · 19.4%
Consumables Product$3.79M · 14.2%
Product Related Services$3.73M · 14.0%
Sample Processing Product Related Services$3.69M · 13.8%
Instruments Product$1.39M · 5.2%
Custom Assay Design Product Related Services$48.4K · 0.2%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-13.76
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing HTG MOLECULAR DIAGNOSTICS against the 5 most active filers in the same SIC group.